title icon
Less relapse. More recovery

We engineer immune cells to be warriors

Overcoming relapse rates in blood born cancers. At Luminary, we are keenly focused on meeting this and many other challenges. We are developing cellular therapies that bring new advances to the table. Our work is helping to deliver new standards of care for specific B-Cell mediated autoimmune diseases. At the same time, we are delivering ground-breaking science for solid tumors. And we are doing this at lower therapy costs.

Less relapse, more recovery, less financial strain. This is our mission.

test tube image
title icon

Three times more likely to bind to the target cancer cells

In the vast universe of CAR-T immunotherapies, there are still challenges to overcome. Our R&D team has recently put forth some eye-opening results. Leading the way is our novel single CAR. Using three receptors, it is designed to overcome a major deficiency of the single antigen CAR–antigen escape. This single antigen approach results in failure rates between 25% and 30%, depending on the type of cancer.

Our 3-receptor CAR first identifies multiple targets on cancer cells. It then surrounds and attaches to these cells in three ways instead of one, allowing fewer escape routes and increasing overall cancer-killing effectiveness.

baff cart-t cell diagram
title icon

Less recurrence. More recovery.

By aggressively pursuing BAFF CAR-T therapy, we add three times the targeting to the equation.
As a result, we expect to lower relapse rates dramatically.

30-60% of cancer patients relapse after CD19 CAR-T cell treatment. Cancer cells evade the immune system by mutating CD19 off the cell surface and the persistence of CAR T-cells.

title icon
Universal Receptor

The Universal Receptor. Cells that can multitask.

Another way Luminary Therapeutics is fighting antigen escape and T-Cell Exhaustion is by outmaneuvering cancer cells. We have developed a synthetic T cell receptor that is armed to bind and kill diverse cancer cells via an interchangeable tumor antigen-binding adapter molecule. We term this T cell engineering platform NORTHSTaR (Nanobody/Retargeting Hapten Synthetic T Cell Receptor). In essence, we arm T Cells with changeable small molecule “warheads.” This converts them to super multitaskers.

“Arming” U-Receptor
Transgenic T cell killing
target cancer cell

Patient treated with
U-Receptor Transgenic T cells
and “arming” small molecule

universal receptor
universal receptor

small molecule

U-Receptor Transgenic
T cells can be “disarmed” in
patient to reverse
off-target toxicities

NORTHSTaR utilizes native TCR signaling, with many demonstrated benefits over CAR molecule signaling:

Reduced Risk of Cytokine Release Syndrome (CRS): TCRs lower cytokine release without loss of killing potency.

Increased Solid Tumor Killing Efficacy: Contrast therapies utilizing TCR signaling are far more effective versus solid tumors.

Reduced T-Cell Overactivation and Exhaustion: TCRs better regulate and reduces over-activation and exhaustion of T cells.

Our approach has the following benefits over others in the cell therapy space:
    • Utilizes FDA-approved small adaptor molecules that demonstrate low immunogenicity and better tissue penetration over peptide-based conjugates.
    • Receptor signaling is TCR-based, not CAR-based, which allows native TCR signaling.
    • Cell source is allogeneic Gamma/Delta T cells as opposed to autologous alpha/beta T-cells.
    • Method of deliver to the T cells is transposon based (TcBuster), allowing for larger cargo capacity and reduced manufacturing costs rather than Lentivirus or CRISPR approaches.
title icon
Non-Viral Allogeneic Platform

Allogeneic is the holy grail. We have broken the code.

Patients need “off the shelf” therapies to reduce time for treatment and cure. Allogeneic solutions are being highly sought. Luminary Therapeutic’s promising Gamma Delta solution is currently in nonclinical evaluation. Expansion rates are high; in vivo pilot studies are underway. Results are very promising.

Unlike other single subset approaches, our Gamma Delta two subset (Vδ1 and Vδ2) solution creates double the response to cancer killing that is both innate and adaptive.

non-viral allogeneic platform

More “adaptive-like”

  • Cytotoxicity against hematological malignancies
  • Less susceptible to activation-induced cell death/exhaustion
  • Multi-year persistence documented in patients
non-viral allogeneic platform

More “innate-like”

  • Abundant in peripheral blood
  • Cytotoxicity against hematological malignancies
  • Readily expanded in vitro (zoledronate)
title icon

Improved quality and reduced risk in the same system

Compared to virus-based systems, non-viral gene editing systems have dramatically changed the manufacturing landscape and improved safety. With higher integration rates and faster manufacturing cycles, these systems are rapidly gaining acceptance in the industry. Luminary Therapeutics utilizes a non-viral gene editing system, TcBuster, to manufacture CAR-T cells. TcBuster was developed by B-MoGen, a company formed by the founders of Luminary , and sold to Bio-Techne prior to the creation of Luminary.

Benefits of TcBuster’s non-viral gene modification:

  • Allows for stable integration of large cargo (>10kb)
  • Preferred integration profile compared to retro/lentiviral vectors
  • Generated GMP grade tranposon reagents in <4 months
  • Lower engineering cost than viral vectors by 75-90%
transposase mRNA